Total Payments
$2.6M
2024 Payments
$205,129
Companies
43
Transactions
1,901
Payment Breakdown by Category
Other$1.2M (44.8%)
Consulting$792,304 (30.1%)
Research$451,772 (17.2%)
Travel$175,079 (6.7%)
Food & Beverage$22,480 (0.9%)
Education$8,121 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 317 | 43.6% |
| Consulting Fee | $792,304 | 307 | 30.1% |
| Unspecified | $451,772 | 356 | 17.2% |
| Travel and Lodging | $175,079 | 536 | 6.7% |
| Honoraria | $31,750 | 7 | 1.2% |
| Food and Beverage | $22,480 | 375 | 0.9% |
| Education | $8,121 | 3 | 0.3% |
Payments by Type
General
$2.2M
1,545 transactions
Research
$451,772
356 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $378,292 | 270 | $0 (2024) |
| Lilly USA, LLC | $363,134 | 286 | $0 (2024) |
| UCB, Inc. | $270,836 | 215 | $0 (2024) |
| Eli Lilly and Company | $255,230 | 134 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $184,061 | 176 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $158,391 | 77 | $0 (2024) |
| GENZYME CORPORATION | $137,520 | 102 | $0 (2023) |
| PFIZER INC. | $126,499 | 60 | $0 (2024) |
| Nielsen BioSciences, Inc. | $119,536 | 2 | $0 (2018) |
| Janssen Scientific Affairs, LLC | $113,793 | 90 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $205,129 | 121 | UCB, Inc. ($92,029) |
| 2023 | $325,906 | 224 | E.R. Squibb & Sons, L.L.C. ($85,354) |
| 2022 | $359,029 | 226 | ABBVIE INC. ($127,536) |
| 2021 | $232,526 | 140 | PFIZER INC. ($40,919) |
| 2020 | $286,273 | 191 | UCB, Inc. ($66,399) |
| 2019 | $326,486 | 276 | AbbVie, Inc. ($100,438) |
| 2018 | $386,986 | 316 | Lilly USA, LLC ($81,799) |
| 2017 | $505,707 | 407 | Nielsen BioSciences, Inc. ($110,759) |
All Payment Transactions
1,901 individual payment records from CMS Open Payments — Page 1 of 77
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $24.24 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| 12/10/2024 | Lilly USA, LLC | — | Travel and Lodging | Cash or cash equivalent | $24.00 | General |
| 11/28/2024 | Amgen Inc. | — | Food and Beverage | Cash or cash equivalent | $33.57 | General |
| 11/28/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $32.00 | General |
| 11/26/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,850.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| 11/21/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| 11/21/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $336.30 | General |
| 11/20/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $504.48 | General |
| 11/14/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 11/14/2024 | Lilly USA, LLC | — | Food and Beverage | Cash or cash equivalent | $150.00 | General |
| 11/14/2024 | Lilly USA, LLC | — | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| 11/13/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,425.00 | General |
| Category: Immunology | ||||||
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,940.00 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $2.54 | General |
| Category: Immunology | ||||||
| 11/09/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $44.89 | General |
| Category: Dermatology | ||||||
| 11/08/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $1,434.97 | General |
| 11/08/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $300.00 | General |
| 11/08/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $223.44 | General |
| 10/28/2024 | Eli Lilly and Company | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| 10/23/2024 | Lilly USA, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CFW-2D | Nielsen BioSciences, Inc. | $119,536 | 2 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $34,160 | 30 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $30,674 | 48 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $27,473 | 3 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $27,465 | 1 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $22,700 | 43 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $13,699 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $12,696 | 16 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $11,600 | 22 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAI | UCB, Inc. | $8,060 | 1 |
| Associations between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, including Corticosteroid Use and Body Mass Index | UCB, Inc. | $6,900 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $6,658 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $5,941 | 6 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $5,580 | 17 |
| Bimekizumab efficacy and safety in the BE READY multicenter, double-blinded, placebo-controlled Phase 3 trial including an initial treatment period followed by a randomised withdrawal period in moderate-to-severe plaque psoriasis | UCB, Inc. | $4,600 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJ | UCB, Inc. | $3,540 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | UCB, Inc. | $3,520 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY INVESTIGATING THE EFFICACY, SAFETY, SERUM CONCENTRATION AND BIOMARKER PROFILE OF DUPILUMAB ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $3,325 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO- AND ACTIVE-CONTROLLED STUDY FOLLOWED BY A PLACEBOCONTROLLED MAINTENANCE PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB, Inc. | $3,120 | 3 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,821 | 6 |
| LONG-TERM EXTENSION TRIAL IN SUBJECTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS TRALOKINUMAB TRIALS - ECZTEND | LEO Pharma AS | $2,700 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,663 | 2 |
| A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $2,635 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $2,525 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY | UCB, Inc. | $2,440 | 6 |
| A practical guide to the management of oral candidiasis in patients with plaque psoriasis receiving treatments that target interleukin-17 | UCB, Inc. | $2,300 | 1 |
| Bimekizumab for patients with moderate- to-severe plaque psoriasis 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled Phase 2b extension study | UCB, Inc. | $2,300 | 1 |
| Bimekizumab for patients with moderate- to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled Phase 2b extension study | UCB, Inc. | $2,300 | 1 |
| Bimekizumab for the treatment of moderate-to-severe plaque psoriasis Efficacy and safety from BE VIVID, a 52-week Phase 3, multicenter, double-blinded, ustekinumab- and placebo-controlled study | UCB, Inc. | $2,300 | 1 |
| Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: Efficacy and safety from BE VIVID, a 52-week Phase 3, multicenter, double-blinded, ustekinumab- and placebo-controlled study | UCB, Inc. | $2,300 | 1 |
| Long Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three Year Results from Two Randomised Phase 3 Trials (CIMPASI 1 and CIMPASI 2) | UCB, Inc. | $2,300 | 1 |
| Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies | UCB, Inc. | $2,300 | 1 |
| Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies | UCB, Inc. | $2,300 | 1 |
| LongTerm Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis ThreeYear Results from Two Randomised Phase 3 Trials CIMPASI1 and CIMPASI2 | UCB, Inc. | $2,300 | 1 |
| A MULTICENTER, 48-WEEK, DOUBLEBLIND, PLACEBO CONTROLLED, PARALLEL-GROUP EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PHASE 2B | UCB, Inc. | $2,060 | 1 |
| Efficacy of Continued Certolizumab Pegol Treatment in Patients with Plaque Psoriasis Showing a Response Between PASI75 and 90 Following the First 16 Weeks of Treatment | UCB, Inc. | $2,060 | 3 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | Regeneron Pharmaceuticals, Inc. | $1,973 | 3 |
| A 52 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND STUDY OF SUBCUTANEOUS SECUKINUMAB TO DEMONSTRATE EFFICACY AS ASSESSED BY PSORIASIS AREA AND SEVERITY INDEX AT 16 WEEKS OF TREATMENT COMPARED TO USTEKINUMAB AND TO ASSESS LONG TERM SAFETY TOLERABILITY AND EFFICACY IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Novartis Pharmaceuticals Corporation | $1,928 | 1 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $1,804 | 1 |
| A Phase I, Open-label Study to Assess the Pharmacokinetics of KY1005 After Single Dose Administration by Subcutaneous and Intravenous Route in Healthy Volunteers | GENZYME CORPORATION | $1,750 | 4 |
| M16-005 | AbbVie Inc. | $1,570 | 2 |
| Publication support research related | Novartis Pharma AG | $1,567 | 1 |
| LIBERTY-AD CHRONOS | SANOFI-AVENTIS U.S. LLC | $1,259 | 2 |
| BODY MASS INDEX AND SYSTEMIC CORTICOSTEROID USE AS INDICATORS OF DISEASE BURDEN AND THEIR INFLUENCE ON THE SAFETY PROFILE OF CERTOLIZUMAB PEGOL ACROSS INDICATIONS | UCB, Inc. | $1,240 | 1 |
| Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies | UCB, Inc. | $1,220 | 2 |
| Treatment Strategies for Patients with Plaque Psoriasis who Respond Inadequately to Certolizumab Pegol During the First 16 Weeks of Treatment | UCB, Inc. | $1,220 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab | Regeneron Pharmaceuticals, Inc. | $1,174 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab | SANOFI-AVENTIS U.S. LLC | $1,002 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $979.37 | 5 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Mo | SANOFI-AVENTIS U.S. LLC | $875.79 | 1 |
| Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled 3-year Efficacy Outcomes from the Intent-to-Treat Population of Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $840.00 | 1 |
| Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis CIMPASI-1, CIMPASI-2, and CIMPACT | UCB, Inc. | $840.00 | 1 |
| Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT | UCB, Inc. | $840.00 | 1 |
| Efficacy of certolizumab pegol in patients with psoriasis and skin of color pooled data from four randomized, placebo-controlled phase 23 trials | UCB, Inc. | $840.00 | 1 |
| Efficacy of certolizumab pegol in patients with psoriasis and skin of color: pooled data from four randomized, placebo-controlled phase 2/3 trials | UCB, Inc. | $840.00 | 1 |
| A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to | UCB, Inc. | $820.00 | 2 |
| Bimekizumab safety in patients with moderate to severe psoriasis Analysis of pooled data from phase 2 and 3 clinical trials | UCB, Inc. | $820.00 | 1 |
| Bimekizumab safety in patients with moderate to severe psoriasis: Analysis of pooled data from phase 2 and 3 clinical trials | UCB, Inc. | $820.00 | 1 |
| Efficacy of Continued Certolizumab Pegol Treatment in Patients Who Inadequately Respond in the First 16 Weeks: Results from the CIMPACT Trial | UCB, Inc. | $820.00 | 2 |
| Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients With Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $820.00 | 1 |
| Long-term improvements in health-related quality of life of patients with moderate to severe plaque psoriasis treated with certolizumab pegol Results from the CIMPASI-1 and CIMPASI-2 phase 3 trials | UCB, Inc. | $820.00 | 1 |
| Long-term improvements in health-related quality of life of patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Results from the CIMPASI-1 and CIMPASI-2 phase 3 trials | UCB, Inc. | $820.00 | 1 |
| Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis: Pooled Analysis from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $820.00 | 2 |
| The Efficacy of Certolizumab Pegol Re-Treatment on Plaque Psoriasis Following a Blinded Treatment Break: Results from the CIMPACT Trial | UCB, Inc. | $820.00 | 1 |
| CAIN457F2336 | Novartis Pharmaceuticals Corporation | $713.00 | 1 |
| A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged 6 to 18 Years With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $504.06 | 1 |
| A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH AN INITIAL TREATMENT PERIOD FOLLOWED BY A RANDOMIZED-WITHDRAWAL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. | UCB, Inc. | $420.00 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS W | UCB, Inc. | $420.00 | 1 |
| A Phase 3 Multicenter, randomized, double-blind, placebo - and active comparator-controlled, parallel group study to evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis results from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial BE SURE | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: results from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial (BE SURE) | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy and safety versus secukinumab in patients with moderate to severe plaque psoriasis Results from a multicenter, randomized, double-blinded, active comparator-controlled phase 3b trial BE RADIANT | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy and safety versus secukinumab in patients with moderate to severe plaque psoriasis: Results from a multicenter, randomized, double-blinded, active comparator-controlled phase 3b trial (BE RADIANT) | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy in patients with moderate to severe plaque psoriasis during the randomized withdrawal and retreatment phase of BE READY, a phase 3 trial | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab Results from the phase 3 BE SURE trial | UCB, Inc. | $420.00 | 1 |
| Bimekizumab efficacy in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab or switching from adalimumab: Results from the phase 3 BE SURE trial | UCB, Inc. | $420.00 | 1 |
| Bimekizumab versus adalimumab in plaque psoriasis Higher efficacy translates to improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial | UCB, Inc. | $420.00 | 1 |
| Bimekizumab versus adalimumab in plaque psoriasis: Higher efficacy translates to improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial | UCB, Inc. | $420.00 | 1 |
| Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study | UCB, Inc. | $420.00 | 1 |
| DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS AN ANALYSIS OF POOLED CLINICAL TRIAL DATA | UCB, Inc. | $420.00 | 1 |
| DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA | UCB, Inc. | $420.00 | 1 |
| Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials | UCB, Inc. | $420.00 | 1 |
| Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) | UCB, Inc. | $420.00 | 1 |
| Durability of Response in Plaque Psoriasis Patients Treated with Certolizumab Pegol: Two Year data from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials | UCB, Inc. | $420.00 | 1 |
| Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT) | UCB, Inc. | $420.00 | 1 |
| Durable Improvement in Patient-Reported Outcomes (PROs) across DLQI Subdomains Over 48 Weeks in Chronic Plaque Psoriasis Patients Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $420.00 | 1 |
| Durable Reduction in Absolute PASI and BSA in Plaque Psoriasis Patients Treated with Certolizumab Pegol Over 48 Weeks in Two Ongoing, Phase 3 Studies (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $420.00 | 1 |
| Efficacy of Certolizumab Pegol Dose Escalation in Patients Who Inadequately Respond to Initial Treatment: Results from the CIMPACT Trial | UCB, Inc. | $420.00 | 1 |
| Efficacy of Certolizumab Pegol in Psoriasis Patients Failing to Respond to Etanercept: Results from an Ongoing, Phase 3, Randomized Controlled Study | UCB, Inc. | $420.00 | 1 |
| Long-Term Improvements in Health-Related Quality of Life across Individual DLQI Items for Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol in Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $420.00 | 1 |
| Long-Term Improvements in Health-Related Quality of Life across Individual DLQI Items for Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol in Two Phase 3 Trials CIMPASI-1 and CIMPASI-2 | UCB, Inc. | $420.00 | 1 |
| Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials | UCB, Inc. | $420.00 | 1 |
| A phase 3, MULTICENTER, double-blind, placebo controlled study with an Initial Treatment period FOLLOWED BY A randomized-withdrawal PERIOD TO EVALUATE THE EFFICACY and safety OF BIMEKIZUMAB IN ADULT S | UCB, Inc. | $400.00 | 1 |
| Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis Results from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial BE SURE | UCB, Inc. | $400.00 | 1 |
| Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: Results from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial (BE SURE) | UCB, Inc. | $400.00 | 1 |
| Clinical response in plaque psoriasis patients switching from etanercept to certolizumab pegol in a phase 3, randomized, controlled study | UCB, Inc. | $400.00 | 1 |
| Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol Three-Year Results from Two Phase 3 Trials CIMPASI-1 and CIMPASI-2 | UCB, Inc. | $400.00 | 1 |
| Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) | UCB, Inc. | $400.00 | 1 |
| Durability of responses with bimekizumab, a selective dual inhibitor of interleukin (IL)-17A and -17F, in moderate-to-severe chronic plaque psoriasis in a 60-week randomized, double-blinded, Phase 2b study (BE ABLE 2) | UCB, Inc. | $400.00 | 1 |
| Durability of responses with bimekizumab, a selective dual inhibitor of interleukin IL-17A and -17F, in moderate-to-severe chronic plaque psoriasis in a 60-week randomized, double-blinded, Phase 2b study BE ABLE 2 | UCB, Inc. | $400.00 | 1 |
| Durable reduction in absolute PASI with certolizumab pegol in patients with chronic plaque psoriasis | UCB, Inc. | $400.00 | 1 |
| Efficacy and Safety of Bimekizumab in Patients with Moderate-to-Severe Plaque Psoriasis Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal | UCB, Inc. | $400.00 | 1 |
| Efficacy and Safety of Bimekizumab in Patients with Moderate-to-Severe Plaque Psoriasis Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study | UCB, Inc. | $400.00 | 1 |
| Efficacy and Safety of Bimekizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal | UCB, Inc. | $400.00 | 1 |
| Efficacy and Safety of Bimekizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study | UCB, Inc. | $400.00 | 1 |
| Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies | UCB, Inc. | $400.00 | 1 |
| Reductions in Absolute PASI Over 144 Weeks of Treatment with Certolizumab Pegol in Patients with Plaque Psoriasis Pooled Analysis from Two Phase 3 Trials CIMPASI-1 and CIMPASI-2 | UCB, Inc. | $400.00 | 1 |
| Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled 96 Week Data from Three Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT) | UCB, Inc. | $400.00 | 1 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | SANOFI-AVENTIS U.S. LLC | $398.25 | 2 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $352.88 | 1 |
| Study of REGN668/SAR231893 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $340.59 | 1 |
| An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $324.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $313.14 | 1 |
| Dupixent Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $292.91 | 2 |
| SOLO 1; SOLO 2 | SANOFI-AVENTIS U.S. LLC | $287.32 | 1 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $250.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB VERSUS PLACEBO IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS | Eli Lilly and Company | $10.95 | 1 |
About Dr. Andrew Blauvelt, MD
Dr. Andrew Blauvelt, MD is a Dermatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932115425.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Blauvelt, MD has received a total of $2.6M in payments from pharmaceutical and medical device companies, with $205,129 received in 2024. These payments were reported across 1,901 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.1M).
Ad
Practice Information
- Specialty Dermatology
- Location Portland, OR
- Active Since 08/01/2006
- Last Updated 08/15/2011
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1932115425
Products in Payments
- TALTZ (Drug) $229,194
- DUPIXENT (Biological) $211,484
- RINVOQ (Biological) $168,545
- DUPIXENT DUPILUMAB INJECTION (Biological) $130,838
- Candin (Biological) $119,536
- DUPIXENT (Drug) $110,853
- Bimzelx (Biological) $90,359
- Tremfya (Drug) $78,731
- Sotyktu (Drug) $72,435
- Olumiant (Drug) $65,129
- Skyrizi (Biological) $57,682
- SKYRIZI (Biological) $52,829
- CIBINQO (Drug) $51,120
- COSENTYX (Biological) $50,393
- ATOPIC DERMATITIS - DISEASE (Drug) $49,255
- Cimzia (Drug) $45,657
- Humira (Biological) $34,648
- OLUMIANT (Drug) $33,595
- STELARA (Biological) $24,031
- OPZELURA (Drug) $14,526
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Portland
Eric Simpson, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Benjamin Ehst, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $1.5M
Dermatology $1.5M
Dr. Jason Hawkes, Md, Ms, MD, MS
Dermatology — Payments: $876,779
Dermatology $876,779
Dr. Omar Qutub, Md, MD
Dermatology — Payments: $73,858
Dermatology $73,858
Alex Ortega Loayza, Md, MD
Dermatology — Payments: $72,824
Dermatology $72,824
Jon Hanifin, Md, MD
Dermatology — Payments: $66,868
Dermatology $66,868